Urinary Biomarkers of OI Pathobiology (NCT02531087)
Cross-Linked Collagen Peptides as a Urinary Biomarker of OI Pathobiology
🩺 Plain-English Summary (8th-Grade Level)
Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain and difficulty getting around. Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.
Who can join: Review the eligibility criteria below.
Location: University of California Los Angeles — Los Angeles, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- University of California Los Angeles — Los Angeles, California
- University of Nebraska Medical Center — Omaha, Nebraska
- Hospital for Special Surgery — New York, New York
- Oregon Health Science University — Portland, Oregon
- Baylor College of Medicine — Houston, Texas
- Shriners Hospital for Children — Milwauke, Wisconsin
- Shriners Hospital for Children — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Osteogenesis Imperfecta
- Dental Malocclusion and Craniofacial Development in OI — Los Angeles, California
- Setrusumab vs Placebo for Osteogenesis Imperfecta — Little Rock, Arkansas
- Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708 — Los Angeles, California
- Clear Aligners for the Treatment of Dental Malocclusion in OI — Los Angeles, California
- Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta — Birmingham, Alabama
- Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta — Phoenix, Arizona
Explore by condition: All Osteogenesis Imperfecta clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.